Wilmington, Delaware 19803

  • Attention Deficit Disorder With Hyperactivity

Purpose:

The aims of this study are to evaluate auditory sensitivity in teenagers with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART.


Study summary:

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Besides core ADHD symptoms (inattentiveness, hyperactivity, impulsivity), ADHD also affects the ability to perceive and process sounds. Both hypersensitivity and hyposensitivity to loud sounds are common symptoms in ADHD patients. With stimulant medication, individuals with ADHD become more tolerant of loud noise than when they were non-medicated. It remains unknown exactly how stimulant medication alters the loudness perception. The proposed study will use the acoustic reflex to objectively measure auditory sensitivity to loud sounds. The aims of this study are to evaluate auditory sensitivity in patients with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART. Eligible participants will participate in two sessions (off-med and on-med conditions) conducted on the same day. ADHD patients will be asked to come to the laboratory before taking their ADHD medication. The investigators will repeat three tests before and after taking stimulant medication. The investigators will also conduct screening tests during and between the first and second sessions. The investigators will compare a difference between the two independent groups (ADHD vs. Control) and compare a within subject difference between medication conditions (on-med vs. off-med).


Criteria:

Inclusion Criteria: Inclusion criteria for all: - Participant must be aged 13 to 19 years - Males and females - All ethnicities - All socioeconomic statuses - Normal hearing - English as a primary language Additional inclusion criteria for ADHD group: - Participants must meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD), all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) - Stimulant medication with the same drug and dosage for at least 1 year before their enrollment date Exclusion Criteria: - History of any major neurological disorders (e.g. seizures excluding febrile seizure under age 6 years, tumors, brain injury, cerebral palsy, tic disorders) - History of any other major neuropsychiatric disorders (e.g. autism spectrum disorder, mood dysregulation), - Presence of pressure equalization tubes in either ear - Documented hearing impairment 20 decibel or higher hearing loss in either ear - Estimated low cognitive function based on the NIH Toolbox Cognition age-corrected scores (<70) Additional exclusion criteria for the ADHD group - Treatment with any psychotropic medications other than stimulants - Treatment with any ADHD medication other than stimulants (e.g. alpha-agonists, norepinephrine reuptake inhibitors) Additional exclusion criteria for the control group • Treatment with any psychotropic medication


NCT ID:

NCT04577417


Primary Contact:

Principal Investigator
Kyoko Nagao, PhD
Nemours

Shelby Sydenstricker, MA
Phone: 302-651-5963
Email: shelby.sydenstricker@nemours.org


Backup Contact:

Email: kyoko.nagao@nemours.org
Kyoko Nagao, PhD
Phone: 302-651-6830


Location Contact:

Wilmington, Delaware 19803
United States

Shelby Sydenstricker, MA
Phone: 302-651-5963
Email: shelby.sydenstricker@nemours.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 02, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.